kelch like family member 41Genealiases: KBTBD10 · Krp1 · SARCOSIN
Q-omics provides the consensus-scored KLHL41 profile across patient tissues and cancer cell-line models. KLHL41 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, KLHL41 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, KLHL41 RNA expression shows 19,083 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, BLCA, and UVM as cancer lineages where KLHL41 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL41 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL41 survival associations across molecular data types. KLHL41 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL41 RNA expression–survival associations across cancer types. High KLHL41 expression shows unfavorable associations in STAD, UVM, HNSC and LGG, but favorable associations in READ and PAAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for KLHL41 RNA expression.
This table summarizes KLHL41 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KLHL41. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL41 shows lower tumor expression in BLCA, KICH, LUAD, HNSC, LUSC and KIRP. The BLCA box plot shows higher KLHL41 RNA expression in normal versus tumor tissue (log2 FC = −4.027, t-test p < 0.001).
This table shows molecular features associated with KLHL41 in patient tissues and cancer cell lines. In patient samples, KLHL41 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL41 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
